NOVN Novan, Inc.

+0  (2%)
Previous Close 5.28
Open 5.28
Price To book 2.71
Market Cap 86.07M
Shares 15,969,000
Volume 78,499
Short Ratio 1.44
Av. Daily Volume 547,571

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met. End of Phase 2 meeting planned for 2Q 2017 with Phase 3 trials to commence by the end of 2017.
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Intends to meet with FDA 3Q 2017 regarding a possible NDA submission 1Q 2018.
Acne vulgaris

Latest News

  1. Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
  2. Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
  3. Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
  4. Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
  5. Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
  6. Novan Gets Positive Phase II Results
  7. Novan's stock rockets after positive trial results
  8. Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
  9. Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
  10. Novan continues to recruit, adds dermatology advisory council
  11. Novan Welcomes Key Opinion Leaders to New Advisory Council
  12. Why Novan (NOVN) Could Be Positioned for a Surge
  13. The focus for FDA approval: Former Quintiles exec moves to Novan
  14. Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
  15. Novan Reshapes Executive Management Team
  16. Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
  17. Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
  18. Novan’s loss grew in 2016, but optimistic on development
  19. Novan reports 4Q loss
  20. Novan Reports Fourth Quarter and Full Year 2016 Financial Results